Department of Obstetrics and Gynecology, School of Medicine, Sayyad Shirazi Hospital, Golestan University of Medical Sciences, Gorgan, Islamic Republic of Iran.
Student Research Committee, Golestan University of Medical Sciences, Gorgan, Islamic Republic of Iran.
Horm Mol Biol Clin Investig. 2020 Nov 25;41(4):hmbci-2020-0018. doi: 10.1515/hmbci-2020-0018.
The main purpose of this study was to compare the effects of two regimens of metformin and insulin therapy on postpartum oral glucose tolerance test (OGTT) results in pregnant women with gestational diabetes mellitus (GDM).
In this single-blind randomized clinical trial (RCT), a total number of 60 pregnant women meeting the inclusion criteria were assigned to two groups with a randomized block design (RBD): insulin therapy (IT) group (30 patients) and metformin therapy (MT) group (30 patients). At baseline, the data were comprised of prenatal maternal age, gestational age, GDM diagnosis, and maternal weight/height. During the postpartum period, 5-cc blood samples were taken from the pregnant women concerned to analyze their fasting blood sugar (FBS) levels. Then, the patients were asked to come back four days and six weeks later after delivery to check the OGTT results. At six weeks postpartum, in addition to OGTT, the glycated hemoglobin (HbAC) test was performed for all mothers. Finally, six weeks after delivery, these mothers were evaluated with regard to weight loss and body mass index (BMI).
Six weeks postpartum, the maternal weight and BMI significantly decreased in the MT group compared with the IT one, while there was no significant difference between both groups at baseline. On the fourth day, the OGTT results in the MT group were significantly lower in comparison with those in the IT group (p=0.012). At sixth weeks postpartum, the OGTT results were comparably lower in the MT group than those reported for the IT one; however, such a difference was not statistically significant (p=0.087).
According to the study results, metformin could be an effective and safe treatment for pregnant women suffering from GDM instead of insulin therapy.
本研究的主要目的是比较二甲双胍和胰岛素治疗方案对妊娠糖尿病(GDM)孕妇产后口服葡萄糖耐量试验(OGTT)结果的影响。
在这项单盲随机临床试验(RCT)中,按照随机区组设计(RBD)将符合纳入标准的 60 名孕妇分为两组:胰岛素治疗(IT)组(30 例)和二甲双胍治疗(MT)组(30 例)。在基线时,数据包括产前母亲年龄、妊娠周数、GDM 诊断和母亲体重/身高。在产后期间,从孕妇身上抽取 5 毫升血液样本以分析其空腹血糖(FBS)水平。然后,要求患者在分娩后四天和六周后回来检查 OGTT 结果。产后六周时,除 OGTT 外,还对所有母亲进行糖化血红蛋白(HbAC)检测。最后,在分娩后六周时,对这些母亲进行体重减轻和体重指数(BMI)评估。
产后六周时,MT 组的母亲体重和 BMI 明显低于 IT 组,而两组在基线时无显著差异。第四天,MT 组的 OGTT 结果明显低于 IT 组(p=0.012)。产后六周时,MT 组的 OGTT 结果低于 IT 组,但差异无统计学意义(p=0.087)。
根据研究结果,二甲双胍可作为 GDM 孕妇的有效且安全的治疗方法,替代胰岛素治疗。